65247-25-8

Usage

Uses

Used in Medicinal Chemistry:
(2-amino-5-bromophenyl)(3-chlorophenyl)methanone is utilized as a key intermediate in the synthesis of pharmaceuticals due to its structural versatility. The presence of both an amino group and a ketone group allows for the creation of a wide range of organic molecules with potential therapeutic applications.
Used in Drug Development:
In the field of drug development, (2-amino-5-bromophenyl)(3-chlorophenyl)methanone serves as a valuable building block for designing new drugs. Its chemical composition, including the bromine and chlorine atoms, offers opportunities for further modifications, enabling researchers to tailor the compound for specific therapeutic targets and applications.
Used in Chemical Synthesis:
(2-amino-5-bromophenyl)(3-chlorophenyl)methanone is also employed in various chemical synthesis processes. Its unique structure allows for the development of new organic compounds that can be used in different industries, including pharmaceuticals, agrochemicals, and materials science.

Upstream product

• 618-46-2 m-Chlorobenzoyl chloride 
• 106-40-1 4-bromo-aniline 
• 7705-07-9 titanium(III) chloride 
• 288391-73-1 5-Bromo-3-(3-chloro-phenyl)-benzo[c]isoxazole 
• 304854-54-4 2-amino-5-bromo-N-methoxy-N-methyl-benzamide 
• 108-37-2 1-bromo-3-chlorobenzene 

Downstream Products

• 406161-72-6 N-[4-bromo-2-(3-chlorobenzoyl)phenyl]acetamide 
• 192185-72-1 tipifarnib 
• 192185-68-5 6-[amino(4-chlorophenyl)-1-methyl-1H-imidazol-5-ylmethyl]-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone 
• 192185-51-6 4-(3-chlorophenyl)-6-[(4-chlorophenyl)hydroxy(1-methyl-1H-imidazol-5-yl)methyl]-1-methyl-2(1H)-quinolinone 
• 288391-74-2 6-bromo-4-(3-chloro-phenyl)-1H-quinolin-2-one 
• 280143-23-9 6-bromo-2-chloro-4-(3-chlorophenyl)quinoline 
• 190898-86-3 6-bromo-4-(3-chloro-phenyl)-2-methoxy-quinoline 
• 192187-32-9 R₁₀₁₇₆₃ 
• 192187-33-0 R₁₀₄₂₀₉ 
• 406162-21-8 (4-chlorophenyl)-[4-(3-chlorophenyl)-2-methoxyquinolin-6-yl]methanone 

Relevant academic research and scientific papers

Rational modification of a candidate cancer drug for use against chagas disease

Chagas disease is one of the major neglected diseases of the world. Existing drug therapies are limited, ineffective, and highly toxic. We describe a novel strategy of drug discovery of adapting an existing clinical compound with excellent pharmaceutical properties to target a pathogenic organism. The protein farnesyltransferase (PFT) inhibitor tipifarnib, now in phase III anticancer clinical trials, was previously found to kill Trypanosoma cruzi by blocking sterol 14a-demethylase (14DM). We rationally developed tipifarnib analogues that display reduced affinity for human PFT to reduce toxicity while increasing affinity for parasite 14DM. The lead compound has picomolar activity against cultured T. cruzi and is efficacious in a mouse model of acute Chagas disease.

Synthesis Routes Towards the Farnesyl Protein Transferase Inhibitor ZARNESTRA

The discovery that post-translational farnesylation of Ras oncoprotein was an essential step in exercising its biological effect led to the design of farnesyl protein transferase inhibitors (FTIs) in order to control growth of tumors bearing Ras mutations. Pre-clinical studies on murine models have confirmed their inhibitory effect on tumor growth and enabled clinical development. R115777 (ZARNESTRA) is currently undergoing clinical evaluation and recent studies have confirmed its antitumor potential and low toxicity. We wish to describe here the chemical synthesis routes that our group have developed to access ZARNESTRA. Wiley-VCH Verlag GmbH & Co. KGaA, 69451 Weinheim, Germany, 2004.

Farnesyl transferase inhibiting 6-heterocyclylmethyl quinolinone derivatives

This invention comprises the novel compounds of formula (I) wherein r, t, y1—y2, R1, R2, R3, R4, R5, R6 and R7 have defined meanings, having farnesyl transf

Heteroaryl-substituted quinolin-2-one derivatives useful as anticancer agents

The present invention relates to compounds of formula 1 and pharmaceutically acceptable salts and solvates thereof wherein R1, R2, R3, R4, R5, R6, R7, R8, R9/sup